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DemyelinationMultiple sclerosis is a demyelinating disease of the central nervous system which only affects humans. This
makes it difﬁcult to study at amolecular level, and to develop and test potential therapies that may change the
course of the disease. The development of therapies to promote remyelination in multiple sclerosis is a key
research aim, to both aid restoration of electrical impulse conduction in nerves and provide neuroprotection,
reducing disability in patients.
Testing a remyelination therapy in the many and various in vivo models of multiple sclerosis is expensive in
terms of time, animals and money. We report the development and characterisation of an ex vivo slice culture
system using mouse brain and spinal cord, allowing investigation of myelination, demyelination and
remyelination, which can be used as an initial reliable screen to select the most promising remyelination
strategies. We have automated the quantiﬁcation of myelin to provide a high content and moderately-high-
throughput screen for testing therapies for remyelination both by endogenous and exogenous means and as
an invaluable way of studying the biology of remyelination.CNS, central nervous system;
tis; LPC, lysophosphatidylcho-
BP, myelin basic protein; NFH,
s).
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Multiple sclerosis (MS) is the commonest cause of disability in
young people in thewesternworld after trauma, with Scotland having
the highest prevalence of patients in the world (1 in 500 people). The
cause of MS is not clear, but its pathology consists of immune
inﬁltration into the central nervous system (CNS), inﬂammation,
demyelination and axonal degeneration (Dubois-Dalcq et al., 2008).
The presence of demyelinating plaques in the CNS corresponds to MS
relapses, but it is axonal degeneration which correlates with
progressive disability (De Stefano et al., 2001; Fisniku et al., 2008).
Myelination of axons allows fast saltatory conduction of electrical
impulses, and provides support bothmechanically and functionally by
cellular communication between the axon and the oligodendrocyte
which produces the myelin sheath. Demyelination of axons reduces
the conduction velocity of nerve impulses, but also makes the axons
vulnerable to degeneration (Franklin and Ffrench-Constant, 2008). In
MS, some demyelinated plaques contain axons which have been
remyelinated, which restores nerve conduction (Duncan et al., 2009;
Smith et al., 1981) and protects the nerve from subsequent
degeneration (Irvine and Blakemore, 2008). There are now anti-inﬂammatory immunomodulatory treatments that reduce the relapse
rate in MS, but there are no current neuroprotective treatments to
reduce progressive disability in MS. Therefore, one neuroprotective
strategy is to try to improve the efﬁciency of remyelination.
Oligodendrocyte precursor cells (OPCs) are the effector cells of
remyelination and these migrate towards demyelinating MS lesions,
proliferate, differentiate and remyelinate axons, but with limited
efﬁciency (Patani et al., 2007; Patrikios et al., 2006; Perier and
Gregoire, 1965; Prineas and Connell, 1979; Raine and Wu, 1993),
which decreases with the age of the patient and the longevity of the
disease (Goldschmidt et al., 2009). Therefore, improvement of the
efﬁciency of remyelination is a major aim within the MS community,
and if accomplished is likely to be of great importance clinically. This
may be achieved either by enhancing endogenous remyelination or by
introducing exogenous cells to stimulate remyelination.
It is not yet possible to follow remyelination reliably in humans,
although some progress is being made into obtaining magnetic
resonance (MR) sequences which correlate with remyelination,
particularly with the use of Magnetisation Transfer Ratio sequences.
PET scan ligands are also being developed to identify and quantify the
amount of myelin present in areas of the MS brain (Stankoff et al.,
2006). In humans, correlation with pathology can only be performed
by doing MR scans on post-mortem brains (Barkhof et al., 2003;
Schmierer et al., 2009), from rare biopsies (Bruck et al., 1997) or by
serendipitous MR scans shortly before a MS patient dies, with
subsequent pathology (Chen et al., 2007). Thus, we must use animal
models of MS to discover and develop new strategies for enhancing
remyelination to reduce axonal degeneration and patient disability.
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myelination and in vivo models of remyelination. In vitro systems
culturing OPCs with CNS or peripheral nervous system neurones are
relatively simple, inexpensive, high-throughput models (Chan et al.,
2004; Lubetzki et al., 1993; Wang et al., 2007; Watkins et al., 2008).
However, they are models of myelination and not remyelination,
which occurs in the presence of inﬂammation, injury and insult. For
this reason, extrapolation of results from in vitro models to in vivo
situations can be unreliable.
In vivo models include experimental allergic encephalitis (EAE),
focal myelin toxin injection and cuprizone ingestion — reviewed in
Blakemore and Franklin (2008) and Furlan et al. (2009). Thesemodels
each reﬂect different aspects of the pathology of MS and are the
current accepted gold standards for modelling the disease, but these
models are very low-throughput, and so expensive in terms of
animals, time and money.
A method of culturing ex vivo rat organotypic slices for electro-
physiological recordings dates back to 1941 (Levi and Meyer, 1941),
but myelination was ﬁrst reported in longer term cerebellar slices in
1956 (Hild, 1956). Demyelination of these slices was achieved as early
as 1959, by adding serum from animals with EAE (Bornstein and
Appel, 1959). However, the technique was developed further to study
myelination when immunohistochemical techniques were fully
developed (Notterpek et al., 1993). In 2004, lysophosphatidylcholine
(LPC) was used to demyelinate rat cerebellar slices, with the
subsequent return of myelin sheaths suggestive of remyelination
(Birgbauer et al., 2004). More recently still, our group and others have
used this technique to investigate the action of exogenous molecules/
drugs on the rate of CNS remyelination (Huang et al., 2011; Mi et al.,
2009; Miron et al., 2010).
However, previously, the slice model has never been characterised
nor validated. We report the further development of this slice model
of CNS remyelination in the mouse cerebellum, brain stem and spinal
cord. We fully characterise the model through myelination, demye-
lination and remyelination, showing that compact myelin is formed,
destroyed and replaced, and that remyelinated axons have shorter
internodes and thinnermyelin.We also have developed an automated
system of quantifying (re)myelination, to enable the use of this model
as a fast and objective screen. We tested the model with factors
known to affect remyelination in vivo to determine the ﬁdelity of our
automated slice quantiﬁcation system to the in vivo situation and
provided proof of principle that exogenous manipulated OPCs added
to slices are able to myelinate axons.
Materials and methods
Animal work was carried out in accordance with the University of
Edinburgh regulations under Home Ofﬁce rules, with local ethical
committee consent.
Slice culture
P1–P2mouse pupswere decapitated, and their brains or spinal cords
were dissected into ice-cold Hank's Balanced Salt Solution (HBSS). 200–
300 μm sagittal slices of cerebellum, brainstem or spinal cord were cut
using a McIlwain tissue chopper. The slices were placed on Millipore
Millicell-CM organotypic culture inserts (Fisher) in medium containing
50%MEMwithEarle's salts, 25% Earle's Balanced Salt Solution, 25%heat-
inactivated horse serum (HIHS), glutamax-II supplement with penicil-
lin–streptomycin, amphotericin B (all purchased from Invitrogen) and
6.5 mg/ml glucose (Sigma).Mediumwas changed every two days. After
10 days in culture, demyelinationwas induced by addition of 0.5 mg/ml
lysophosphatidylcholine (lysolecithin, LPC, Sigma) to the medium for
15–20 h, after which slices were transferred back into normal medium.
Cerebellar slice cultures require around 16 h, whereas brainstem and
spinal cord cultures require around 18 h of incubation. Concentrationsof LPC higher than this are also toxic to axons. Medium containing
factorswas added 12 h later. Factors usedwere Platelet Derived Growth
Factor (PDGF) (10 ng/ml, teproTech Inc.), Fibroblast growth factor (FGF)
(10 ng/ml, teproTech Inc.), Neuregulin 1 (NRG1) (10 ng/ml, R&D
Systems), NRG1-III (10 ng/ml, R&D Systems), DAPT (gamma secretase
inhibitor, 5 μM, CalBiochem), 9-cis retinoic acid (9cRA, 50 nM, Sigma),
9cRA agonists HX630 and PA024, and 9cRA antagonist PA452 (1 μM,
500 nM, 5 μM respectively, kindly supplied by Hiroyuki Kagechika).
Cultures were maintained for a further 14 days, and then processed for
immunolabelling. For proliferation assays, BRDU (Roche) was added for
16 h to the culture medium before ﬁxation at DIV10 (myelination M),
DIV12 (demyelination DM) and DIV25 (remyelination RM).
Immunoﬂuoresence
Slices were ﬁxed while attached to membranes with 4% parafor-
maldehyde (PFA) in phosphate-buffered saline (PBS) for 1 h, rinsed in
PBS for 10 min thrice, and blocked with 3% HIHS, 2% bovine serum
albumin (BSA), and 0.5% Triton X-100 in PBS for 1 h. Slices were then
incubated in primary antibody overnight, washed once for 10 min and
then thrice for 1 h. The slices were then incubated in secondary
antibody overnight, washed thrice and mounted. The antibodies
Nkx2.2 and PCNA required antigen retrieval before incubation with
the primary antibody, by microwaving in Vector H-3300 antigen
unmasking solution (Vector Laboratories) for 5 min. Antibodies used
include: contactin associated protein (Caspr, mouse, 1 in 500, Abcam),
CD68 (mouse, 1 in 200, Serotec), myelin basic protein (MBP, rat, 1 in
500, Serotec), neuroﬁlament (NFH, chick, 1 in 50,000, EnCor),
Neuronin N (NeuN, 1 in 300, Chemicon), Nkx2.2 (rabbit, 1 in 200,
Developmental Studies Hybridoma Bank, University of Iowa), NG2
(mouse, 1 in 200, Chemicon), Olig2 (goat, 1 in 40, R & D systems),
Periaxin (1 in 2000, Repeat Periaxin antibody, kindly supplied by P.J.
Brophy), PCNA (rabbit, 1 in 2000, Abcam) and BrdU (mouse, 1 in 500,
Chemicon). Appropriate ﬂuorescent secondary antibodies were used
(Alexa Fluor, Invitrogen).
Transmission electron microscopy (EM)
Samples were ﬁxed in 2.5% glutaraldehyde in 0.1 M sodium
cacodylate buffer, pH 7.3, for 2 h, washed in PBS and post-ﬁxed in
1% osmium tetroxide in 0.1 M sodium cacodylate for 45 min. The
samples were then dehydrated in increasing concentrations of
acetone and embedded in Araldite resin. Sections, 1 μm thick, were
cut on a Reichert OMU4 ultramicrotome (Leica Microsystems),
stained with toluidine blue and viewed in a light microscope to select
suitable areas for investigation. Ultrathin sections, 60 nm thick were
cut from selected areas, stained in uranyl acetate and lead citrate and
then viewed in a Phillips CM120 Transmission electron microscope
(FEI). Images were taken on a Gatan Orius CCD camera (Gatan). The
perimeter of the axon and the outer border of the myelin sheath was
traced and measured with Image Pro Plus software (Media Cyber-
netics). The G ratio was obtained by dividing these values. The axon
diameter was measured by taking the average length of diameters
measured at 2° intervals and passing through the centre of the axon.
The Maximum Likelihood Test was used to test the likelihood that the
two G-ratio regression lines were statistically different.
Quantiﬁcation
Confocal microscopy was used to obtain stacks of photographs of
MBP and NFH immunolabelling at 1 μm intervals in white matter
areas at ×40 magniﬁcation. Slices thinned after culture for 25 days to
approximately 30 μm thickness. Myelinated ﬁbres are best observed
between a depth of 5 μm to 20 μm from the upper surface and all our
results were taken from this level. A macro was written with Image
Pro Plus software (Media Cybernetics) to automate quantiﬁcation of
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the stack and the pixels where there was overlap of red and green
within a predeﬁned intensity were highlighted forming a mask of co-
localization. Very small areas of pixels positive for overlap were
excluded automatically to avoid artefact (area under 30 pixels, area of
1 pixel=72264 nm2). Then, the area covered by positive (over-
lapping) pixels was measured. A similar procedure was performed for
NFH staining and the two measurements divided to form the
“Myelination Index” — as a measure of the amount of myelin sheath
per axon area. The macro written within the programme platform
performs all these steps automatically, in around 10 s per image stack.
Comparison of the effect of factors on the Myelination Index and
proliferation was analysed statistically using ANOVA, followed by the
Dunnett's Multiple Comparison Test. Data comparing multiple factors
on theMyelination Index is presented normalised to the control group
(no additive) which is given the Myelination Index of 1.
Internodal lengths were measured from merges of photographs of
slices stained with MBP, NFH and Caspr, and the distance between
Caspr staining at paranodes was traced using ImageJ. Comparison of
the frequency-distribution of internode length was analysed statisti-
cally using the Kolmogorov–Smirnov Test for non-normally distrib-
uted data.
Addition of virally-transduced OPCs to slices
Mouse OPCs were isolated using the shake-off method described
previously (McCarthy and de Vellis, 1980) and plated onto poly-D-
lysine coated 6 well plates. Lentivirus containing a GFP sequence with
a post-transcriptional enhancer under the Cytomegalovirus (CMV)
promoter (engineered from Invitrogen pLenti6) and with a Vesicular
Stomatitis Virus (VSV) envelope protein, was added to the OPCs at a
concentration of 50 particles per cell for 4 h (kindly provided by
Pamela Brown). OPCs were maintained in a proliferative state for
2 days with addition of PDGF (10 ng/μl) and FGF (10 ng/μl) and 2%
foetal calf serum in Dulbecco's modiﬁed Eagles medium. The cells
were then trypsinised using TrypLE express solution (Gibco) for
5 min, spun down at 1000 rpm and resuspended in slice culture
medium. These cells were pipetted directly onto slices (approximately
10,000 to each slice) and the cultures maintained for 14 days. GFP-
containing oligodendrocytes were visible directly with a ﬂuorescent
microscope, and the cultures were co-stained for MBP and NFH as
described above.
Results
Myelination, demyelination and remyelination occurs in slice cultures
Slices of cerebellum, brainstem and spinal cord between 200 and
300 μm in thickness are taken from postnatal day 1–2mice and placed
in culture (Fig. 1A). Myelination occurs readily, and is extensive by
10 days in vitro (DIV). The gliotoxin lysophosphatidyl choline (LPC) is
added at 10 DIV for 15–20 h which leads to almost complete
demyelination 24 h after LPC is removed. After 14 additional days in
culture (25 DIV), myelin sheaths reappear in conjunction with
contactin-associated protein (Caspr) localised at the paranodes
around a node, suggestive of a mature myelin internode (Fig. 2E).
The angle of cutting the sections is critical, and requires sagittal
sections to minimise nerve ﬁbre damage. Cerebellar slices are much
more successful if not detached from the brainstem (Fig. 1B), possibly
related to both the maintained connectivity of Purkinje cells and the
higher concentration of OPCs in brainstem than cerebellum. Only
slices with a maintained neural architecture should be used, for
reasons of consistency, which in our hands amounts to about four
cerebellar slices attached to brainstem, and three spinal cord slices per
mouse. Using these criteria for selection of the slices, the results are
consistent between multiple experiments. The concentration andtime of LPC addition is also critical as too high a concentration or too
long an application also causes axon degeneration. Spinal cord, with
its densely packed myelin sheaths (Fig. 1C), requires a longer
application of LPC before complete demyelination, probably due to
slower LPC penetration (see Materials and methods).Characterisation of the cells in the model
In MS, cells at the heart of the demyelinating lesion die, activated
microglia/macrophages migrate to the lesion to clear this debris, OPCs
migrate to the lesions, proliferate and then differentiate to success-
fully remyelinate the lesion. OPCs are present in slice cultures as
shown by antibody staining to NG2 and are retained after LPC
treatment (Fig. 2A). At 25 DIV, we saw mature oligodendrocytes
myelinating axons, (MBP positive, Fig. 2B) with clear internodes,
heminodes and nodes of Ranvier, ﬂanked by paranodes, identiﬁed by
tightly localised Caspr expression (Fig. 2E). This is suggestive
immunohistochemical evidence that maturation of the myelin sheath
occurs, with the formation of specialised nodal and paranodal
structures. Cells with a Schwann cell phenotype, the effectors of
myelination in the peripheral nervous system, do not myelinate axons
in this system as seen by the absence of staining with a periaxin
antibody (data not shown).
Activated microglia/macrophages are seen in these cultures, as
shown by antibodies to CD68 (Fig. 2C). In MS lesions, macrophages
are also recruited from the blood, which is absent in our model, but
there are sufﬁcient resident microglia/macrophages to clear most
debris. Axonal bulbs, indicative of axonal damage, are sometimes seen
after demyelination in our slice model. These are reminiscent of those
seen in MS lesions (Dutta and Trapp, 2007) (Fig. 2D).OPCs proliferate in response to demyelination
Using antibodies against the marker of proliferation PCNA
(proliferating cell nuclear antigen), we showed that treatment with
LPC causing demyelination provoked a proliferative response, which
subsided with remyelination. The number of proliferating cells in
cerebellar/brainstem slices increased 3.2 fold the day after demyelin-
ation (DM) (12 DIV) compared to at 10 DIV in control myelinated (M)
slices. At 25 DIV (remyelination), the number of proliferating cells had
returned to levels indistinguishable from control myelinated slices
(M) (Figs. 3A–D). Some of these proliferating cells are oligodendrog-
lial cells as shown by using antibodies to Olig2 and Nkx2.2. The
number of cells double positive for Olig2 and PCNA increased 2.4-fold
the day after demyelination (DM) (12 DIV) compared to at 10 DIV in
control myelinated (M) slices. At 25 DIV (remyelination), the number
of proliferating cells had returned to levels indistinguishable from
control myelinated slices (M) (Figs. 3A–C, E). Similar results were
seen with immunohistochemistry to Nkx2.2 (data not shown).
Therefore, demyelination stimulates oligodendroglial proliferation in
slice cultures as well as in MS brain. This increase in proliferation of
OPCs was also seen by using BrdU incorporation, with a 3.7-fold
increase in BrdU-positive OPCs the day after demyelination (DM)
(12 DIV), compared to at 10 DIV in control myelinated (M) slices,
returning to basal rates at 25 DIV (remyelination) (Figs. 3F and G).
Addition of PDGF, a known stimulus of OPC proliferation in vitro
(Wang et al., 2007) and in vivo (Woodruff et al., 2004), further
promotes proliferation in slice cultures, both at 10 DIV, with a 2.4-fold
increase in the basal rate of proliferation, and after demyelination
(12 DIV), with a 1.2-fold increase in numbers of proliferating cells
compared to slices in the absence of PDGF (Figs. 3F and G). All cultures
are grown in 25% horse serum, containing some PDGF and other
growth factors, but even so, addition of exogenous PDGF caused an
increase in proliferation over and above that of control cultures.
Put in culture
Day 1 Day 10 Day 25
LPC 15 - 20 hrs Fix
200-300µm200-300µm
Myelination Demyelination Remyelination
MBP MBP MBP
200-300µm
A
MBP/NFH
B C
MBP/NFH
Fig. 1. Summary of culture method. A) Slices from cerebellum, brain stem and spinal cord are cultured and allowed to myelinate. By day 10, myelination, as assessed by Myelin Basic
Protein (MBP) immunoﬂuorescence (green) is robust. Lysophosphatidyl choline (LPC) is added to the culture medium on day 10, and MBP immunostaining shows only myelin
debris. Remyelination is assessed at day 14 after LPC treatment and MBP staining shows the return of myelinated internodes. Scale bar 10 μm. B–C) Cerebellum with attached
brainstem (B) and spinal cord (C) showing axons (immunoﬂuorescence to NFH, red) and myelin (immunoﬂuorescence to MBP, green) at 10 DIV. Scale bars 100 μm. (Images taken
with ×20 objective and stitched together.)
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We considered the possibility that the apparent return of myelin
sheaths in our slice system represents myelination of previously
unmyelinated nerve ﬁbres. Remyelinated myelin sheaths are thinner
andhave shorter internodal lengths compared tomyelin sheaths formed
in development (Perier and Gregoire, 1965; Prineas and Connell, 1979).
To investigate whether the return of myelin sheaths after LPC treatment
represents genuinely remyelinated ﬁbres, we performed electron
microscopy on cerebellar slices, to measure G-ratios (Figs. 4A–C).
Myelinated ﬁbres were measured after 10 DIV and “remyelinated”
ﬁbres at 25 DIV, with demyelination on day 10. The G ratio represents
the ratio of the diameter of the axon to the diameter of the myelinated
ﬁbre and allows comparison ofmyelin thickness for different axon sizes.
There was a marked difference between the groups, with “remyeli-
nated” ﬁbres having higher G ratios and thus thinner myelin sheaths.The curves of best ﬁt through the points are shown in Fig. 4D, and these
are statistically signiﬁcantly different using the maximum likelihood
ratio test (pb0.05).Remyelinated ﬁbres have shorter internodes
Wemeasured the lengths of themyelin sheaths in both cerebellum
and spinal cord, by measuring the distance between paranodes,
labelled with anti-Caspr antibodies. We saw that the frequency of
short myelin sheaths at 25 DIV (with demyelination on day 10) was
much higher than in initial myelination (10 DIV) (Figs. 4E and F). The
Caspr staining of paranodes, which reappears in remyelination, plus
the compaction of the myelin sheaths seen by electron microscopy,
suggests that these remyelinated ﬁbres are mature. Fully formed
nodes of Ranvier were also identiﬁed (Fig. 4C). Thus, myelin sheaths
fNFH
D
B
MBP/NFH
A
NG2
E
CD68/Hoechst
C
MBP/NFH/Caspr
F
GFP/MBP/NFH
Fig. 2. Characterisation of the cells in the model. A) NG2 positive cells (green) show that oligodendrocyte precursor cells (OPCs) are present and remain after demyelination of slices.
B) Mature oligodendrocytes (immunoﬂuorescence to MBP, green) remyelinate axons (immunoﬂuorescence to NFH, red) in slice cultures. The photo is overexposed to show the
oligodendrocyte arms linking the cell body andmyelin sheaths. C) Microglia stained with antibodies to CD68 (green) and Hoechst (blue) showing that resident microglia are present
in slices. D) After demyelination, axonal bulbs can be seen, reminiscent of those seen in MS plaques (immunoﬂuorescence to NFH, red.) E) Nodes of Ranvier reform after
remyelination (MBP green, NFH red, Caspr, white). F) Exogenous OPCs, transduced with lentiviral vectors to express cytoplasmic GFP, can be added to slices, and are able to
myelinate axons. GFP ﬁlls the cytoplasmic channels of the myelinating process, whereas MBP antibody stains the myelin sheath GFP green, MBP red, NFH blue). Arrow — GFP+
oligodendrocyte cell body. Arrowheads — limit of a myelinated internode seen by the gap in red MBP staining and limit of cytoplasmic GFP staining. Scale bars 10 μm.
142 H. Zhang et al. / Experimental Neurology 230 (2011) 138–148that reappear after LPC treatment are thinner and shorter than before,
pathognomonic of remyelination.
Automatic quantiﬁcation of (re)myelination after immunohistochemistry
There is no previously published automated quantiﬁcation ofmyelin
sheaths. Previously, the amount of myelination has been measured by
measuring CNPase activity (Birgbauer et al., 2004; Roth et al., 1995), but
this is a marker of differentiation of oligodendrocytes, rather than the
presence of myelin sheaths. Similarly, an approach using a beta-
galactosidase luminometric assay in a transgenicmouse expressing LacZunder theMBPpromoter onlymeasuresMBPexpression rather than the
formation of myelin sheaths (Stankoff et al., 1996). The amount of
immunoﬂuorescence staining for MBP has also been used (Ghoumari
et al., 2003;Mi et al., 2009;Miron et al., 2010) but this does not allow for
the number of axons present (a prerequisite for remyelination), and
MBP is present in oligodendrocyte processes and cell bodies as well as
myelin sheaths. Recently, it was also described that retinoic acid
increased MBPmRNA and protein expression in Schwann cell bodies in
the peripheral nervous system, but reduced myelinated internodes
(Latasa et al., 2010), indicating that MBP protein alone is not an ideal
measure of myelination. A fast, accurate, objective and automatic
143H. Zhang et al. / Experimental Neurology 230 (2011) 138–148quantiﬁcation of the amount of myelin is essential in order to use our
model to study factors inﬂuencing myelination or remyelination in a
high-throughput manner.M
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144 H. Zhang et al. / Experimental Neurology 230 (2011) 138–148oligodendrocyte cell bodies and non-myelinating processes, we
measured the overlap between red and green staining at ×40
objective, to quantify only MBP staining overlying axons— the myelin
sheaths. We have capitalised on the fact that at this resolution, MBP
staining appears to overlie NFH staining, which is lost at higher
resolution.We used Image Pro Plus software to write a macro to count
pixels which are both red and green above a deﬁned intensity overlap
(Fig. 5B) for each layer within a confocal stack, producing a “mask”
(Fig. 5C). We exclude extremely small areas of overlap to exclude
artefact, forming an “enhanced mask” representing myelinated
internodes (Fig. 5D). The number of pixels in the “enhanced mask”
is divided by the number of red pixels in the photograph of
neuroﬁlament staining only (Figs. 5E and F), obtaining the “Myelina-
tion Index”. With this macro, analysis of a stack of images takes
around 10 s. This method is fast, objective (not inﬂuenced by user
preconceptions) and avoids counting most cell bodies.
To test whether this quantiﬁcation system is sensitive enough to
detect changes in myelination, we used it to measure myelination in
the cerebellar slice system at 4 DIV, 8 DIV and 12 DIV. Themyelination
index increases in a linear way with time, with signiﬁcant differences
between each time point (Fig. 6A) (ANOVA plus Dunnett's multiple
comparison test *pb0.01).Validation of the slice model for in vivo remyelination
Addition of various factors to in vitro co-culture models of
developmental myelination have been shown to alter myelination.
However, several of these factors fail to affect remyelination in in vivo
models (summarised and referenced in Table 1). We tested these
known factors in our cerebellar slice model for their inﬂuence on
remyelination, in order to test the ﬁdelity of our slice system to the in
vivo situation. We tested two factors which promote the proliferation
of OPCs and decrease myelination in vitro but do not affect
myelination in vivo: Platelet Derived Growth Factor (PDGF) and
Fibroblast Growth Factor (FGF). We used NRG1, NRG1 type 3 and
DAPT (which inhibits γ-secretase), as these promote myelination
in culture, though are not effective in remyelination in vivo. We used
9-cis retinoic acid (9cRA) which promotes remyelination in vivo, and
the Retinoic acid receptor X (RXR) antagonist PA452, which reduces
myelination in vitro (Huang et al., 2011). We also used two speciﬁc
RXR agonists (HX630 and PA025) to show that the effect was speciﬁc
to the RXR receptor. Each of these factors was added 24 h after the
removal of LPC from the culture, and replenished every second day.
The myelination index for each factor tested in the slice model is
shown in Fig. 6B. As summarised in Table 1, we found that only factors
inﬂuencing remyelination in vivo inﬂuenced remyelination in our slice
model. Of note, we found that although PDGF addition promoted OPC
proliferation (Figs. 3F and G), as found in vitro (Wang et al., 2007), it
did not change the rate of remyelination in our slice model, which is
reﬂected in its failure to improve remyelination in vivo (Woodruff
et al., 2004). This suggests that use of our slicemodel of remyelination,
using the myelination index for quantiﬁcation, is predictive of the in
vivo effect, both in positively predicting those that have an in vivo
effect and negatively predicting those that do not.Fig. 3. Oligodendroglial cells proliferate in response to demyelination and PDGF. Immunoﬂuo
a subset of which are Olig2-positive oligodendroglial cells (red (B)), withmerge in (C). Scale
as deﬁned by immunoreactivity against PCNA, increased from 10 DIV (myelination — M)
(remyelination — RM). E) A subset of these proliferating cells is oligodendroglial cells. C
(myelination — M), to 12 DIV (demyelination — DM — one day after LPC) and then subsi
Multiple Comparison Test. Unit area=100,000 μm2.) F) Addition of PDGF (10 ng/ml) to the
(white). (Scale bar 100 μm). G) There is an increase in proliferation of OPCs in slices after add
10 DIV (myelination — M), 12 DIV (demyelination — DM — one day after LPC) and 25 DI
**pb0.01, *pb0.05, ANOVA and Dunnett's Multiple Comparison Test. N=2 experiments. UExogenous OPCs added to slice cultures can integrate and form myelin
sheaths
Therapies to enhance remyelination aim to either stimulate
remyelination by endogenous oligodendroglial cells, or aim to add
exogenous cells to fulﬁl this role. Puriﬁed rat OPCs added to mouse
cerebellar slices treated with cytosine arabinoside to prevent
endogenous myelination, previously achieved some successful mye-
lination presumed to be myelination of mouse axons by rat
oligodendroglial cells (Nishimura et al., 1985). We tested whether
manipulated exogenous OPCs added to slices can incorporate into the
structure, mature and myelinate. We transduced mouse OPCs with
lentivirus expressing GFP and pipetted these directly onto cerebellar
slices. After 14 days, some GFP-positive OPCs were attached only to
the culture membrane, or the edge of the slice, but others penetrated
into the slice tissue and myelinated axons (Fig. 2F). We have similarly
achieved myelination by adding GFP-positive neurospheres to slices.
Thus endogenous and exogenous OPCs form myelin sheaths in our
slice model, allowing testing of therapies enhancing both strategies
for improving remyelination.
Discussion
The clinical importance of a validated, robust, high content and
moderately-high-throughput system to test putative pro-remyelinat-
ing compounds is potentially large. We demonstrate that we have
developed such a system enabling us to test the effect of therapies on
endogenous remyelination and by the addition of exogenous cells to
enhance remyelination.
As in demyelinating lesions in vivo, we show that OPCs in our slice
system proliferate in response to demyelination, that macrophages
are present to clear myelin debris, and that the return of myelin
sheaths after demyelination represents compact myelin with charac-
teristics of remyelination. We have automated quantiﬁcation of
myelination, making it objective and reducing analysis time signiﬁ-
cantly. Although truly high throughput screening would be impossi-
ble in this system, it allows us to test tens of compounds over a period
of a month, in comparison to several years for testing the same
number of compounds in vivo. Only the most promising strategies
could then be tested in vivo, saving much in terms of time and
resources.
On testing the system with factors known to alter myelination in
vitro, some of which also alter remyelination in vivo, the slice model
results were consistent with the in vivo remyelinationmodel. This is in
spite of using early postnatal mouse brain grown for 10 days in
culture, which may be more plastic than adult brain. Remyelination
shares similarities with myelination, but also has signiﬁcant differ-
ences as remyelination occurs on axons which are demyelinated
(whichmay change them) in the presence of inﬂammatory debris and
tissue injury.
Cerebellar slice cultures have the advantage that most myelinated
axons are of one type — Purkinje cell axons. However, brain stem and
spinal cord slices myelinate more robustly than cerebellum in culture
and contain a mixture of ﬁbre types and diameters. This is perhaps
more reﬂective of the situation in both development and MS, which isrescence for PCNA (green (A)) shows actively proliferating cells in a demyelinated slice,
bar— 10 μm. D) The number of cells proliferating in cerebellum/brainstem slice cultures,
, to 12 DIV (demyelination — DM — one day after LPC) and then subsided by 25 DIV
ells double positive for Olig2 and PCNA similarly increased in number from 10 DIV
ded by 25 DIV (remyelination — RM). (Mean+S.D., *pb0.001, ANOVA and Dunnett's
culture medium increased the proliferation of OPCs as assessed by BRDU incorporation
ition of PDGF, at each stage, compared to control, as measured by BRDU incorporation at
V (remyelination — RM) (Mean+S.D., comparisons with control at each time-point.
nit area=1 mm2).
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Fig. 4. Return of myelin sheaths represents true remyelination. A) Electron micrograph of myelinated axons from cerebellum at 10 DIV. Scale bar — 1 μm. B) Electron micrograph of
remyelinated axons from cerebellum at 25 DIV, after LPC treatment on day 10. Note the thinner myelin per axon, especially in relation to their axon diameter. Scale bar — 1 μm.
C) Electron micrograph showing a node of Ranvier present in cerebellar cultures that were allowed to remyelinate. Thus, compact myelin forms with mature paranodal structures.
Scale bar — 1 μm. D) Quantiﬁcation of G ratios showing larger G ratios (thinner myelin) for remyelinated axons (dark grey) than that of myelinated axons (pale grey), per axon
diameter. These regression lines are signiﬁcantly different using the maximum likelihood ratio test, pb0.01 (counted from 6 cerebellar slices per group). E–F) Frequency distribution
graphs of internode length in myelinated (E) and remyelinated (F) axons in the cerebellum (pale grey) and spinal cord (dark grey). There is a left shift for remyelinated axons
showing that these have shorter internodes. (N=4 experiments, a minimum of 80 internodes counted per group.) Comparisons of myelination and remyelination frequency-
distribution data for both cerebellum and spinal cord is signiﬁcant with pb0.01 (Kolmogorov–Smirnov Test).
145H. Zhang et al. / Experimental Neurology 230 (2011) 138–148not nerve ﬁbre type speciﬁc. Spinal cord contains a pool of OPCs from
different developmental sources compared to brain (Vallstedt et al.,
2005) and is linear, and may be used for OPC migration experiments
using local sources of chemotactic molecules. Sagittal slices of cerebral
cortex have also been cultured, and the corpus callosum also shows
myelination (Supplementary Fig. 1).
As our slice system uses mouse tissue, it can be used to examine
remyelination in slices from transgenic animals. This allows quickerassessment of their remyelination capacity, but also more detailed
assessment of the biology as it can be easily assessed at different time-
points and even used in combination with time-lapse microscopy to
watch events in real-time. We have shown that lentiviruses can be
used to manipulate the biology of the slices. Lentiviral transduction of
slices is highly efﬁcient and can be used to add genes under cell-
speciﬁc promoters, or reduce protein expression using mi/si/shRNA
technology. In the case of conditional and inducible transgenic mice,
A B
MBP/NFH
NFH
Enhanced mask of myelin
Mask of axons
Mask
C D
E F
Fig. 5. Automatic quantiﬁcation of (re)myelination. A) Merge of immunoﬂuorescence for MBP (green) and NFH (red) showing overlap. B) Selection of the intensity range
corresponding to overlap to be scored as positive (within green line).C) A mask is formed of the overlapping areas (white). D) Overlap areas are coloured orange — excluding
predeﬁned very small areas— and quantiﬁed, corresponding to the amount of myelin. E) Immunoﬂuorescence for NFH (red) only for the same photograph. F) A mask of all positive
pixels for the colour red, corresponding to amount of axons. The Myelination Index (amount of myelin per axon) is determined by dividing the amount of myelin (D) by the amount
of axons (F). This quantiﬁcation takes less than 10 s and avoids counting MBP staining in oligodendrocyte cell bodies (present in green in (A) but excluded in (C)). Scale bar 10 μm.
146 H. Zhang et al. / Experimental Neurology 230 (2011) 138–148viruses could be used to induce Cre expression and excise the gene of
interest, or the system could be induced with tamoxifen/doxycycline
to investigate the biology ex vivo, before deciding to invest much
effort, time and money in breeding mice for lengthy in vivo
experiments. Semliki Forest viruses have also successfully been usedto transduce oligodendrocytes in mouse hippocampal slice cultures,
enabling them to be tracked by live imaging (Haber et al., 2009).
We have also shown that OPCs can be manipulated in culture with
lentiviruses, added to slices, and migrate into slices to myelinate
axons. This is a proof of principle that the action of exogenous cells can
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Fig. 6. Validation of Myelination Index and model for cerebellar slices. A) The
Myelination Index increases linearly between 4 days in vitro and 12 days in vitro,
showing that this method is sensitive enough to detect changes in amount of myelin.
*pb0.01, ANOVA and Dunnett's Multiple Comparison Test. (N=2 experiments, a
minimum of 7 slices counted per condition.) B) Factors previously used to try and alter
remyelination were added to the culture medium 24 h after demyelination, and
remyelination assessed 14 days after. The data is normalised to the control (no
additive) data. Fibroblast growth factor (FGF), Platelet Derived Growth Factor (PDGF),
Neuregulin 1 (NRG1), NRG1-III and DAPT (gamma secretase inhibitor) addition showed
no difference compared to the controls (control — no additive, PBS added, DMSO
added). However, 9 cis-retinoic acid (9cRA) signiﬁcantly enhances remyelination, and
its antagonist PA452 signiﬁcantly inhibits remyelination. Speciﬁc agonists of the RXR
receptor, HX630 and PA024 also enhance myelination and this effect is reversed by the
use of the antagonist PA452 (Mean+S.D., * pb0.05 in comparison to control, ANOVA
and Dunnett's Multiple Comparison Test) (N=3 experiments, a minimum of 7 slices
counted per condition). This is in concordance with in vivo remyelination experiments
after demyelination with a myelin toxin in rodents (see Table 1).
147H. Zhang et al. / Experimental Neurology 230 (2011) 138–148be studied in our system. We predict that OPCs derived from
embryonic/ induced pluripotent stem cells will incorporate similarly
and so this system can also be used to screen stem cell based therapies
to enhance remyelination.
The pathology of MS is complex and exclusively human, so no
model of the disease is perfect. Our system models remyelination, aTable 1
Comparison of effect of factors on myelination and remyelination.
Factor Action on OPCs Myelination in
PDGF ↑ Proliferation ↓ Myelination (
FGF2 ↑ Proliferation ↓ Myelination (
NRG1 ↑ Proliferation and survival ↑ Myelination (
Inhibition of γ-secretase/Notch-1 ablation ↑ Differentiation ↑ Myelination (
9-cis retinoic acid ↑ Differentiation ↔ Myelinationkey therapeutic target in MS for prevention of axonal degeneration.
We aimed to model active demyelinating MS plaques, which often
have some propensity to remyelinate, rather than chronic MS plaques
which do not. Our system does notmodel the inﬂammatory pathology
of MS, as althoughmicroglia are present, there is no blood supply, and
so T and B cell inﬁltrates are not present. Thus, its use is similar to that
of the in vivo MS models using myelin toxins to cause demyelination
and study remyelination, rather than EAE. The advantage of these
systems is that remyelination can be studied without the complexity
of ongoing inﬂammation.
We present this automated slice system as an appropriatemodel of
in vivo remyelination in the rodent CNS, and as a model of pathology
inMS.We suggest that it can be used as an intermediate step between
in vitro experiments and undertaking lengthy in vivo studies, to select
the most promising compounds, though clearly not replacing the
latter. Using the slice system in this way will reduce live animal usage
and has a large potential for studying therapeutics and biology of
remyelination and even neuroprotection, accelerating the translation
of compounds from mouse to man.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.expneurol.2011.04.009.Acknowledgments
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